Please assess the completion status of the following clinical trial:

Trial Title: ssTAP vs TAP Catheters in TAH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo total abdominal hysterectomy~* Age ≥ 18 years.~* American Society of Anesthesiologists (ASA) physical status ≤ 3~Exclusion Criteria:~* Known coagulopathy~* Known allergy to Bupivacaine or morphine~* Contraindication to Tylenol usage~* Medical conditions contraindicated to bupivacaine use~* Daily narcotic usage for ≥ 2 weeks of 20mg of oxycodone daily or an equivalent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wound Infiltration (Type: PLACEBO_COMPARATOR): 0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
- TAP Blocks (Type: EXPERIMENTAL): 20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
- TAP Catheters (Type: EXPERIMENTAL): 20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).